OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday.
Other equities analysts have also recently issued research reports about the stock. Jefferies Group boosted their price target on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price target on shares of OncoMed Pharmaceuticals in a research report on Thursday, July 14th. Zacks Investment Research upgraded shares of OncoMed Pharmaceuticals from a “sell” rating to a “hold” rating and set a $11.00 price target on the stock in a research report on Wednesday, October 12th. Finally, Leerink Swann restated a “market perform” rating and issued a $13.00 price objective on shares of OncoMed Pharmaceuticals in a report on Monday, October 10th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $19.25.
Shares of OncoMed Pharmaceuticals (NASDAQ:OMED) traded down 0.83% during trading on Wednesday, reaching $9.59. 37,286 shares of the company traded hands. OncoMed Pharmaceuticals has a 12-month low of $8.07 and a 12-month high of $23.98. The stock’s market capitalization is $355.71 million. The firm’s 50 day moving average is $9.72 and its 200-day moving average is $11.42.
OncoMed Pharmaceuticals (NASDAQ:OMED) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.77). OncoMed Pharmaceuticals had a negative net margin of 409.54% and a negative return on equity of 1,307.23%. The company had revenue of $5.92 million for the quarter, compared to analysts’ expectations of $9.48 million. During the same quarter in the previous year, the company earned ($0.81) earnings per share. OncoMed Pharmaceuticals’s quarterly revenue was up 26.3% on a year-over-year basis. On average, equities research analysts anticipate that OncoMed Pharmaceuticals will post ($3.23) earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in OMED. Bogle Investment Management L P DE acquired a new stake in shares of OncoMed Pharmaceuticals during the first quarter worth $1,131,000. A.R.T. Advisors LLC purchased a new position in shares of OncoMed Pharmaceuticals during the first quarter valued at about $832,000. Barclays PLC increased its position in shares of OncoMed Pharmaceuticals by 916.3% in the first quarter. Barclays PLC now owns 117,537 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 105,972 shares in the last quarter. BVF Inc. IL increased its position in shares of OncoMed Pharmaceuticals by 35.1% in the first quarter. BVF Inc. IL now owns 1,339,336 shares of the biopharmaceutical company’s stock valued at $13,541,000 after buying an additional 347,903 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of OncoMed Pharmaceuticals during the second quarter valued at about $162,000. Institutional investors and hedge funds own 31.95% of the company’s stock.
About OncoMed Pharmaceuticals